- In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.
- * Subject's parent/legal guardian has voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- * Male or female subject who has completed their Visit 13 (Study Day 366 for non-naïve subjects) or clinic Visit 15 (Day 390 for naïve subjects) in parent trial V118_05.
- * For naïve subjects in parent trial V118_05 to have received two doses of the same study vaccine (i.e. 2 doses of aQIV or 2 doses of QIV).
Influenza
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
NCT02583256 | PHASE 3 | INTERVENTIONAL
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118_05. Subjects will receive either the Same or Alternate Type of Vaccine.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Investigational Site
Espoo,Etelä-Suomen Lääni,Finland,02230
Investigational Site
Helsinki,Etelä-Suomen Lääni,Finland,00100
Investigational Site
Helsinki,Etelä-Suomen Lääni,Finland,00100
Investigational Site
Järvenpää,Etelä-Suomen Lääni,Finland,04400
Investigational Site
Kokkola,Länsi-Suomen Lääni,Finland,67100
Investigational Site
Pori,Länsi-Suomen Lääni,Finland,28100
Investigational Site
Tampere,Länsi-Suomen Lääni,Finland,33100
Investigational Site
Turku,Länsi-Suomen Lääni,Finland,20520
Investigational Site
Oulu,Finland,90220
Investigational Site
Laguna,Matro Manila,Philippines,1781
Investigational Site
Muntinlupa,National Capital Region,Philippines,1781
Investigational Site
Muntinlupa,National Capital Region,Philippines,1781
Investigational Site
Cavite,Philippines,4114
Investigational Site
Pathum Thani,Bangkok,Thailand,12120
Investigational Site
Bangkok,Krung Thep Maha Nakhon [Bangko,Thailand,10400
Investigational Site
Bangkok,Samut Prakan,Thailand,10400
Investigational Site
Bangkok,Thailand,10330
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov